Ricardo V Lloyd

Summary

Affiliation: University of Wisconsin
Country: USA

Publications

  1. doi request reprint Stem cells and cancer stem-like cells in endocrine tissues
    Ricardo V Lloyd
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, K4 436 CSC 8550, Madison, WI 53705, USA
    Endocr Pathol 24:1-10. 2013
  2. pmc Papillary thyroid carcinoma variants
    Ricardo V Lloyd
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Head Neck Pathol 5:51-6. 2011
  3. doi request reprint Adrenal cortical tumors, pheochromocytomas and paragangliomas
    Ricardo V Lloyd
    Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Mod Pathol 24:S58-65. 2011
  4. pmc RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 35:101-11. 2009
  5. ncbi request reprint Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas
    Long Jin
    Department of Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Endocr Pathol 16:107-14. 2005
  6. pmc The role of epithelial mesenchymal transition markers in thyroid carcinoma progression
    Celina Montemayor-Garcia
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, K4 436 Clinical Science Center, Box 8550, 600 Highland Avenue, Madison, WI, 53792, USA
    Endocr Pathol 24:206-12. 2013
  7. ncbi request reprint Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 30:299-306. 2006
  8. ncbi request reprint Effects of DNA methylation on galectin-3 expression in pituitary tumors
    Katharina H Ruebel
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Cancer Res 65:1136-40. 2005
  9. pmc Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas
    Darya Buehler
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, K4 436 Clinical Science Center, Madison, WI, USA
    Mod Pathol 26:54-61. 2013
  10. doi request reprint Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors
    Peter M Sadow
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Endocr Pathol 19:97-103. 2008

Collaborators

Detail Information

Publications27

  1. doi request reprint Stem cells and cancer stem-like cells in endocrine tissues
    Ricardo V Lloyd
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, K4 436 CSC 8550, Madison, WI 53705, USA
    Endocr Pathol 24:1-10. 2013
    ..New discoveries in this field may lead to more effective therapies for highly aggressive and lethal endocrine cancers...
  2. pmc Papillary thyroid carcinoma variants
    Ricardo V Lloyd
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Head Neck Pathol 5:51-6. 2011
    ....
  3. doi request reprint Adrenal cortical tumors, pheochromocytomas and paragangliomas
    Ricardo V Lloyd
    Department of Pathology, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Mod Pathol 24:S58-65. 2011
    ..Hereditary paraganglioma syndromes with mutations of SDHB, SDHC and SDHD are associated with paragangliomas and some pheochromocytomas...
  4. pmc RUNX1 and RUNX2 upregulate Galectin-3 expression in human pituitary tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 35:101-11. 2009
    ....
  5. ncbi request reprint Galectin-3 Expression in Functioning and Silent ACTH-Producing Adenomas
    Long Jin
    Department of Pathology, Mayo Clinic and Mayo Foundation, Rochester, MN 55905, USA
    Endocr Pathol 16:107-14. 2005
    ..The use of ACTH and Gal-3 immunostaining should help in the diagnosis of silent ACTH adenomas...
  6. pmc The role of epithelial mesenchymal transition markers in thyroid carcinoma progression
    Celina Montemayor-Garcia
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, K4 436 Clinical Science Center, Box 8550, 600 Highland Avenue, Madison, WI, 53792, USA
    Endocr Pathol 24:206-12. 2013
    ....
  7. ncbi request reprint Association of DNA methylation and epigenetic inactivation of RASSF1A and beta-catenin with metastasis in small bowel carcinoid tumors
    He Yu Zhang
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, MN 55905, USA
    Endocrine 30:299-306. 2006
    ..The other six genes did not show significant differences. These results suggest that increased methylation of RASSF1A and CTNNB1 may play important roles in progression and metastasis of small bowel carcinoid tumors...
  8. ncbi request reprint Effects of DNA methylation on galectin-3 expression in pituitary tumors
    Katharina H Ruebel
    Department of Pathology, Mayo Clinic College of Medicine, Rochester, Minnesota, USA
    Cancer Res 65:1136-40. 2005
    ..Because it is functionally involved in cancer progression and metastasis, Gal-3 may serve as a possible therapeutic target in the treatment of pituitary tumors...
  9. pmc Expression of epithelial-mesenchymal transition regulators SNAI2 and TWIST1 in thyroid carcinomas
    Darya Buehler
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, K4 436 Clinical Science Center, Madison, WI, USA
    Mod Pathol 26:54-61. 2013
    ..Our findings support the role of epithelial-mesenchymal transition in the development of anaplastic thyroid carcinoma...
  10. doi request reprint Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors
    Peter M Sadow
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Endocr Pathol 19:97-103. 2008
    ..These results show that stathmin is expressed at higher levels in more rapidly proliferating endocrine tumors. However, it is probably not useful as a stand-alone marker to determine malignancy in pheochromocytomas for individual tumors...
  11. pmc Postoperative surveillance of small appendiceal carcinoid tumors
    Sara E Murray
    Section of Endocrine Surgery, Department of Surgery, University of Wisconsin, K4 739 Clinical Science Center, 600 Highland Avenue, Madison, WI 53792, USA
    Am J Surg 207:342-5; discussion 345. 2014
    ..The necessity and frequency of postoperative surveillance for appendiceal carcinoid tumors ≤1 cm are undetermined...
  12. doi request reprint Thyroid cancer stem-like cells and epithelial-mesenchymal transition in thyroid cancers
    Heather Hardin
    Department of Pathology and Laboratory Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA
    Hum Pathol 44:1707-13. 2013
    ..New discoveries in this field may lead to more effective therapies for highly aggressive and lethal thyroid cancers. ..
  13. doi request reprint Pituitary blastoma
    Bernd W Scheithauer
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Acta Neuropathol 116:657-66. 2008
    ....
  14. ncbi request reprint Pituitary carcinoma: a clinicopathological review
    Bernd W Scheithauer
    Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, Minnesota 55901, USA
    Neurosurgery 56:1066-74; discussion 1066-74. 2005
    ..Recent studies have only begun to shed light on the probable mechanisms of tumor initiation and progression. A review of the clinicopathological and molecular genetic characteristics of pituitary carcinomas is presented...
  15. doi request reprint Immunoexpression of androgen receptor in the nontumorous pituitary and in adenomas
    Bernd W Scheithauer
    Department of Pathology and Laboratory Medicine, Mayo Clinic, Rochester, MN 55905, USA
    Endocr Pathol 19:27-33. 2008
    ..No staining of thyroid-stimulating hormone adenomas was noted. The physiologic significance of our findings remains to be explored. The literature regarding AR expression in animal and human pituitaries is reviewed...
  16. pmc Clinicopathologic characteristics of colonic carcinoid tumors
    Sara E Murray
    Section of Endocrine Surgery, Department of Surgery, University of Wisconsin, Madison, Wisconsin 53792, USA
    J Surg Res 184:183-8. 2013
    ..Few studies have examined the clinicopathologic profile and behavior of this rare tumor...
  17. doi request reprint The spectrum of papillary thyroid carcinoma variants
    Elham Khanafshar
    Department of Pathology, University of California San Francisco, 1600 Divisadero Street, San Francisco, CA 94115, USA
    Adv Anat Pathol 18:90-7. 2011
    ....
  18. ncbi request reprint Combined sellar fibrosarcoma and prolactinoma with neuronal metaplasia: report of a case unassociated with radiotherapy
    Mario Moro
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Endocr Pathol 15:149-58. 2004
    ..Despite the intimate association of both elements in our lesion, no transition of adenoma to sarcoma was demonstrable by immunohistochemistry or in situ hybridization studies...
  19. pmc The North American Neuroendocrine Tumor Society consensus guideline for the diagnosis and management of neuroendocrine tumors: pheochromocytoma, paraganglioma, and medullary thyroid cancer
    Herbert Chen
    Department of Surgery, University of Wisconsin, Madison, WI 53792 7375, USA
    Pancreas 39:775-83. 2010
    ..Genetic testing for RET mutations has allowed identification of familial cases and prophylactic thyroidectomy for cure. The only curative treatment is complete surgical resection...
  20. ncbi request reprint The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems
    David S Klimstra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Pancreas 39:707-12. 2010
    ....
  21. doi request reprint Clinicopathological and molecular characterization of nine cases of columnar cell variant of papillary thyroid carcinoma
    Jey Hsin Chen
    Department of Pathology, Brigham and Women s Hospital, Boston, MA, USA
    Mod Pathol 24:739-49. 2011
    ....
  22. pmc Racial disparity in breast cancer and functional germ line mutation in galectin-3 (rs4644): a pilot study
    Vitaly Balan
    Department of Pathology, Karmanos Cancer Institute, School of Medicine, Wayne State University, Detroit, Michigan, USA
    Cancer Res 68:10045-50. 2008
    ..The data implicate galectin-3 H(64) in breast cancer and explain, in part, the noted racial disparity, thus providing a novel target for diagnosis and treatment...
  23. ncbi request reprint Immunohistochemical expression of neuroendocrine secretory protein-55 (NESP-55) in pituitary adenomas
    Mamta Gupta
    Department of Pathology, Johns Hopkins Medical Center, Weinberg 2268 East Baltimore Campus 401 N Broadway, Baltimore, MD 21231, USA
    Endocr Pathol 22:150-4. 2011
    ..Since immunohistochemical expression of NESP-55 is largely confined to prolactinomas and GH adenomas, it raises the possibility that NESP-55 may somehow be involved in the secretory pathways of these specific cell types...
  24. doi request reprint Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set
    David S Klimstra
    Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Am J Surg Pathol 34:300-13. 2010
    ..Examination of the areas of disagreement reveals significant opportunities for collaborative study to resolve unanswered questions...
  25. ncbi request reprint Pancreatic intraepithelial neoplasia in heterotopic pancreas: evidence for the progression model of pancreatic ductal adenocarcinoma
    Lizhi Zhang
    Department of Pathology, Mayo Clinic, Rochester, MN 55905, USA
    Am J Surg Pathol 31:1191-5. 2007
    ..The presence of PanIN in heterotopic pancreas from patients with ductal adenocarcinoma supports the progression model...
  26. doi request reprint Observer variation in the application of the Pheochromocytoma of the Adrenal Gland Scaled Score
    David Wu
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Am J Surg Pathol 33:599-608. 2009
    ..We consequently suggest that PASS requires further refinement and validation. We cannot currently recommend its use for clinical prognostication...
  27. ncbi request reprint Differential expression of galectin-3 in pituitary tumors
    Dominik Riss
    Department of Pathology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA
    Cancer Res 63:2251-5. 2003
    ..Inhibition of Gal-3 gene expression by RNA interference decreased HP75 cell proliferation and increased apoptosis. These results indicate that Gal-3 has an important role in pituitary cell proliferation and tumor progression...